Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Blackstone follows Abingworth, but why?
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?